Strong Momentum Drives New 52-Week High
The stock’s surge to Rs.2181 represents a significant milestone, reflecting a 1.40% gain on the day and outperforming its sector by 2.43%. This marks the third consecutive day of gains, with a cumulative return of 3.75% over this period. Notably, Acutaas Chemicals is trading above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling sustained bullish momentum.
Comparatively, the stock’s 1-day performance of 1.12% contrasts favourably with the Sensex’s decline of 0.85%, while its 1-week return of 4.62% outpaces the Sensex’s negative 1.04%. Over the past month, Acutaas Chemicals has delivered an impressive 31.42% gain, dwarfing the Sensex’s modest 1.28% rise.
Exceptional Long-Term Performance
Acutaas Chemicals’ long-term returns further highlight its market leadership. The stock has generated a remarkable 91.61% return over the last year, significantly outperforming the Sensex’s 10.92% gain. Year-to-date, the stock has appreciated by 27.43%, while the benchmark index has declined by 3.09%. Over three years, the company’s stock has surged by an extraordinary 374.85%, compared to the Sensex’s 38.88% rise.
While the company’s 5-year and 10-year returns are recorded as zero, this is likely due to data availability or listing timelines. Nonetheless, the recent multi-year performance firmly establishes Acutaas Chemicals as a market outperformer within the Pharmaceuticals & Biotechnology sector.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Financial Strength and Operational Excellence
Acutaas Chemicals’ financial metrics underpin its strong market performance. The company maintains a low average Debt to Equity ratio of zero, indicating a debt-free balance sheet that supports financial stability and flexibility. Net sales have grown at an annualised rate of 26.84%, while operating profit has expanded at an even faster pace of 38.56%, reflecting efficient cost management and operational leverage.
Net profit growth has been particularly impressive, rising by 47.82% as per the latest results declared in December 2025. This marks the sixth consecutive quarter of positive results, demonstrating consistent profitability and resilience.
Key Efficiency Ratios Highlight Operational Quality
The company’s return on capital employed (ROCE) for the half-year period stands at a robust 21.30%, signalling effective utilisation of capital resources. Inventory turnover ratio is high at 5.74 times, indicating efficient inventory management, while the debtors turnover ratio of 3.76 times reflects strong receivables collection processes.
Institutional investors hold a significant 38.38% stake in Acutaas Chemicals, suggesting confidence from well-resourced market participants who typically conduct thorough fundamental analysis.
MarketMojo Ratings and Rankings
Acutaas Chemicals is rated as a Strong Buy by MarketsMojo, with a Mojo Score of 82.0. This represents an upgrade from a previous Buy rating on 6 October 2025, reflecting improved fundamentals and market positioning. The company ranks among the top 1% of over 4,000 stocks covered by MarketsMojo, securing the 5th position among Small Cap stocks and 17th across the entire market universe.
The Market Cap Grade is 3, indicating a mid-sized market capitalisation relative to peers. The stock’s market-beating performance is evident not only in the short term but also over extended periods, including 3 months, 1 year, and 3 years, where it has consistently outperformed the BSE500 index.
Curious about Acutaas Chemicals Ltd from Pharmaceuticals & Biotechnology? Get the complete picture with our detailed research report covering fundamentals, technicals, peer analysis, and everything you need to decide!
- - Detailed research coverage
- - Technical + fundamental view
- - Decision-ready insights
Valuation and Profitability Metrics
Despite its strong growth, Acutaas Chemicals carries a premium valuation. The company’s return on equity (ROE) stands at 15.8%, while the price-to-book (P/B) ratio is elevated at 12.4, indicating a very expensive valuation relative to book value. This premium is higher than the average historical valuations of its peers in the Pharmaceuticals & Biotechnology sector.
Over the past year, the stock’s return of 92.14% has been accompanied by a 136% increase in profits, resulting in a price/earnings-to-growth (PEG) ratio of 0.5. This suggests that the stock’s price growth is supported by strong earnings expansion, although the valuation remains on the higher side.
Summary of Acutaas Chemicals’ Market Journey
Acutaas Chemicals Ltd’s ascent to a new all-time high of Rs.2181 is the culmination of sustained financial discipline, operational efficiency, and consistent earnings growth. The company’s ability to outperform both its sector and broader market indices over multiple time horizons highlights its competitive positioning within the Pharmaceuticals & Biotechnology industry.
Its upgraded Strong Buy rating and high Mojo Score reflect the quality of its fundamentals and market sentiment. While valuation metrics indicate a premium, the company’s strong profit growth and efficient capital utilisation provide a solid foundation for its current market valuation.
Overall, the stock’s record high price today is a testament to Acutaas Chemicals’ successful execution of its business strategy and its standing as a leading small-cap stock in the Indian market.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
